<DOC>
	<DOC>NCT01646424</DOC>
	<brief_summary>The aim of this study is to describe patient preferences on budesonide/formoterol fix dose combination for the treatment of their COPD, and to find those factors more strongly associated to a better attitude to medication.</brief_summary>
	<brief_title>Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description>Validation of questionnaire and assessment of patient satisfaction for budesonide/formoterol fix combination DPI in COPD</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Provision of subject informed consent and to be an outpatient Clinical diagnosis of COPD according to ICD10 classification, females and males, aged â‰¥ 40 years To be prescribed a fixed dose combination of inhaled budesonide/formoterol fix combination at least 3 months before the study start Pregnancy for women Use of inhaled medication via a metered dose inhaler (pMDI) Currently participating in randomized clinical trials and being included in this study once</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>COPD,</keyword>
	<keyword>Patient satisfaction,</keyword>
	<keyword>fix combination,</keyword>
	<keyword>NIS Turkey,</keyword>
	<keyword>turbuhaler,</keyword>
	<keyword>FSI-10</keyword>
</DOC>